SpecificityThis antibody blocks specifically with Dynorphin B 1-13. Cells are found in the paraventricular hypothalamic and the supraoptic nucleus in rat brain of colchicine treated 4% FA perfused tissue. Fibers are found in the lateral hypothalamus of both colchicine and normal rat brain of 4% FA perfused tissue.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. PubMed: 20206610
1/250 - 1/2500.
FunctionLeu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. Dynorphin peptides differentially regulate the kappa opioid receptor. Dynorphin A(1-13) has a typical opiod activity, it is 700 times more potent than Leu-enkephalin. Leumorphin has a typical opiod activity and may have anti-apoptotic effect.
Involvement in diseaseDefects in PDYN are the cause of spinocerebellar ataxia type 23 (SCA23) [MIM:610245]. Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA23 is an adult-onset autosomal dominant form characterized by slowly progressive gait and limb ataxia, with variable additional features, including peripheral neuropathy and dysarthria.
Sequence similaritiesBelongs to the opioid neuropeptide precursor family.
Post-translational modificationsThe N-terminal domain contains 6 conserved cysteines thought to be involved in disulfide bonding and/or processing.
References for Anti-Dynorphin B antibody (ab11135)
This product has been referenced in:
Amrein I & Slomianka L A morphologically distinct granule cell type in the dentate gyrus of the red fox correlates with adult hippocampal neurogenesis. Brain Res1328:12-24 (2010).
Read more (PubMed: 20206610) »